Radioactive drug takes aim at Hard-to-Treat cancers
NCT ID NCT07261631
First seen Jan 04, 2026 · Last updated Jun 20, 2026 · Updated 21 times
Summary
This early-stage trial is testing a new radioactive drug (177Lu-DFC413) to see if it is safe and can shrink tumors in people with advanced solid cancers like pancreatic, lung, breast, colorectal, and sarcoma. About 180 adults whose cancer has progressed after standard treatments will receive the drug. The study also tests a companion imaging agent (68Ga-NNS309) to help see where the drug goes in the body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Novartis Investigative Site
RECRUITINGMontreal, Quebec, H3T 1E2, Canada
-
Novartis Investigative Site
RECRUITINGOdense C, 5000, Denmark
-
Novartis Investigative Site
RECRUITINGVandœuvre-lès-Nancy, 54511, France
-
Novartis Investigative Site
RECRUITINGEssen, 45147, Germany
-
Novartis Investigative Site
RECRUITINGHaifa, 3109601, Israel
-
Novartis Investigative Site
RECRUITINGTel Aviv, 6423906, Israel
-
Novartis Investigative Site
RECRUITINGSingapore, 119228, Singapore
-
Novartis Investigative Site
RECRUITINGSingapore, 168583, Singapore
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
a radioactive drug (177Lu-DFC413) and a diagnostic imaging agent (68Ga-NNS309)
What this could lead to
If successful, this could point toward a new targeted radiation treatment for several hard-to-treat cancers.
What could go wrong
This is an early Phase 1 trial with only 180 participants, so the main goal is safety, not proof of effectiveness. The treatment may cause side effects or not shrink tumors.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.